SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMYLIN PHARM.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: the Chief who wrote (41)9/28/1997 4:31:00 PM
From: D.Right   of 52
 
Dear Chief:

I agree with Michael Murphy. According to my rough calculation, AMLN should have at least $11 sales per current share three years after they have pramlintide on the market. It should be on the market in 1999 (submission for FDA approval scheduled for late next year). I have some analysis of AMLN's situation on the other AMLN thread (post #608 and #823 for example). In my view, the bargain was created by Wall Street's negative reaction towards an actually posivtie result. Although Wall Street makes mistakes all the time, it does the catch-up game very well once the fact is in. As investors, the best opportunity we have to invest is when Wall Street makes mistakes.

Good luck.

D.Right
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News